Klaus Orlinger

 
Introduction
 

Klaus Orlinger is a notable figure in the pharmaceutical and biotechnology field, currently serving as the Chief Scientific Officer (CSO) at HOOKIPA Pharma Inc., based in Austria. His journey in the scientific community is characterized by a solid educational background and extensive professional experience focused on research and development in virology and vaccines.

 
Educational Background
 

Klaus embarked on his academic journey at the University of Vienna, where he earned his Master of Science (MSc) in Microbiology and Genetics in 2004. Following this, he pursued a Doctor of Philosophy (PhD) in Microbiology and Genetics at the Medical University of Vienna, completing it in 2007. His educational background laid a strong foundation for his future roles in the biotech and pharmaceutical industries.

 
Early Professional Career
 

In June 2007, Klaus began his professional career as a Scientist at Baxter Healthcare in Orth an der Donau. He worked there until February 2012, honing his skills in various research methodologies and gaining valuable experience in the healthcare sector.

 
Career at HOOKIPA Pharma Inc.
 

Klaus's notable contributions began to shine when he joined HOOKIPA Pharma Inc., a company specializing in the development of immunotherapeutics. He started as the Head of Virology in February 2012, where he led research and development on vaccine design and played a crucial role in pipeline projects and clinical trial applications.

 
Progression to Senior Roles
 

As his career progressed, Klaus took on increasingly senior roles within the company. From January 2017 to January 2019, he served as the Vice President of Research, focusing on the research and development for vaccine design and leading the pipeline and immunotherapy projects. His contributions were instrumental in generating vaccine seed viruses and spearheading research collaborations.

In January 2019, Klaus was promoted to Senior Vice President of Research, a role where he continued to emphasize virology and preclinical research and development (R&D). His responsibilities expanded as he became Executive Vice President of Research in March 2020, overseeing Virology, Preclinical, Translational, and Clinical Biomarker Departments. He was also responsible for international research collaborations and the representation of the company in project team meetings with executives and investors.

 
Current Role as Chief Scientific Officer
 

In January 2022, Klaus ascended to the position of Chief Scientific Officer (CSO) at HOOKIPA Pharma Inc. In this role, he continues to drive research and development efforts, focusing on the creation and characterization of vaccines and furthering the company's mission in developing innovative immunotherapeutics.

 
Expertise and Contributions
 

Klaus Orlinger possesses a diverse set of skills essential for the biotech and pharmaceutical industries. His expertise includes molecular biology, PCR, biochemistry, biotechnology, and the pharmaceutical industry, among others. He is proficient in tools like Microsoft Office, Microsoft Excel, and PowerPoint, essential for data analysis, presentations, and research documentation.

Throughout his career, Klaus has demonstrated a commitment to advancing scientific research and development, contributing significantly to the fields of virology and vaccine development. His journey from a Scientist to the CSO at HOOKIPA Pharma Inc. is a testament to his dedication, expertise, and leadership in the biotech and pharmaceutical sectors.